Vyleesi in Your 50s: What Women in Menopause Need to Know About Bremelanotide

What Is Vyleesi and How Does It Work in a Menopausal Body?

Vyleesi (bremelanotide) is a melanocortin receptor agonist. You inject it under the skin of your abdomen or thigh about 45 minutes before sex, and it acts on melanocortin 4 (MC4R) receptors in the central nervous system to modulate dopamine and other pathways involved in sexual motivation. It does not act on hormones. That distinction matters a great deal at this life stage.

In your 50s, your hormonal environment has shifted fundamentally. Estrogen falls sharply in the two to three years around the final menstrual period, and testosterone declines more gradually across the entire reproductive lifespan, reaching roughly half of its peak by the late reproductive years. Research published in the Journal of Sexual Medicine confirmed that androgen decline is steady from the mid-30s onward, not a sudden menopause-related drop, but estrogen withdrawal during menopause adds a distinct layer: genitourinary syndrome of menopause (GSM), mood changes, sleep disruption, and body-image shifts that all feed into reduced desire.

Bremelanotide bypasses ovarian hormone levels entirely. It does not raise estrogen or testosterone. Whether that central, non-hormonal mechanism is enough to address desire problems that are partly driven by GSM, vaginal dryness, or pain with sex is a genuinely open clinical question, and the honest answer is: probably not on its own.

How the Menopausal Brain Changes the Response to MC4R Agonism

Estrogen modulates dopaminergic tone. After menopause, lower estrogen may reduce the baseline dopamine responsiveness that bremelanotide is trying to amplify. Preclinical data in rodent models showed that estrogen priming increased melanocortin-driven sexual behavior, suggesting the drug may work differently, or less powerfully, in a low-estrogen environment. That rodent work has not been formally replicated in a phase 3 human trial in postmenopausal women, and clinicians should not assume equivalence.

What the RECONNECT Trials Actually Enrolled

The two phase 3 RECONNECT trials (Study 301 and Study 302) that supported FDA approval enrolled premenopausal women aged 21 to 55 with naturally cycling or surgically induced premenopausal status. Postmenopausal women were excluded. The trials showed a statistically significant but modest improvement: about 0.5-point increase on the desire domain of the Female Sexual Function Index (FSFI) and a reduction in distress scores compared to placebo. The number of satisfying sexual events per month increased by roughly 0.7 events above placebo. These are real but small effect sizes.

Is Vyleesi FDA-Approved for Women in Their 50s or After Menopause?

No. The FDA label specifies premenopausal women. The 2019 FDA approval does not include postmenopausal women, and no supplemental approval for that population has been granted.

Off-label prescribing is legal in the United States, and some clinicians do prescribe bremelanotide to perimenopausal or recently postmenopausal women with HSDD when other options have not worked or are contraindicated. Off-label use is not inherently wrong, but it does carry an added responsibility: you and your prescriber are making a decision without direct phase 3 efficacy data in your population.

Perimenopause vs. Postmenopause: A Meaningful Distinction

Your 50s often span two distinct hormonal states. Perimenopause, the transition typically lasting four to ten years before the final period, involves wildly fluctuating estrogen and progesterone alongside regular or irregular cycles. After your final period, defined as 12 consecutive months without a menstrual bleed, you are postmenopausal.

Women in early perimenopause in their early 50s who still have cycles may technically fall within the spirit of the RECONNECT enrollment criteria, even if the trials did not analyze this subgroup separately. Women who are fully postmenopausal are clearly outside the approved indication. This distinction affects how your clinician should frame the risk-benefit conversation with you.

HSDD Prevalence in Women in Their 50s

Low desire is extremely common at this life stage. A 2008 analysis of the Women's International Study of Health and Sexuality (WISHeS) found that HSDD affected approximately 9% of premenopausal women and 12% of naturally postmenopausal women aged 20 to 70, with distress being the defining feature that separates HSDD from simply having a lower libido without distress. If you are not bothered by reduced desire, it is not HSDD by definition.

Side Effects and Safety Considerations Specific to Women Over 50

Side effects do not exist in a vacuum. At 50-plus, your cardiovascular baseline, skin, blood pressure, and medication list are all different from a 30-year-old's, and those differences change how you weigh each risk.

Nausea

Nausea is the most frequently reported side effect. In the RECONNECT trials, approximately 40% of women using bremelanotide reported nausea, compared to roughly 1% on placebo. Most nausea peaks within one hour of injection and resolves within two hours. Your prescriber may recommend taking a 25 mg ondansetron tablet about 30 minutes before the injection to blunt nausea, though this adds a second drug interaction to consider.

Transient Blood Pressure Rise

Bremelanotide causes a transient, dose-dependent increase in blood pressure that typically peaks 12 minutes after injection and resolves by 12 hours. The mean systolic increase was 6 mmHg and diastolic 3 mmHg in clinical trials. For a woman in her 50s with normal blood pressure, this may be clinically irrelevant. For a woman with stage 1 or stage 2 hypertension, already common in this age group as estrogen-related vascular protection declines, this matters significantly.

The FDA label states that bremelanotide is contraindicated in women with cardiovascular disease, including uncontrolled hypertension. The American Heart Association estimates that hypertension prevalence in women rises from about 31% in the 45 to 54 age group to over 56% in the 55 to 64 age group. That means a substantial portion of women in their 50s may be disqualified from using Vyleesi on cardiovascular grounds.

Skin Hyperpigmentation

With repeated use, bremelanotide can cause focal hyperpigmentation, particularly on the face, gums, and breasts, due to its activity at melanocortin 1 receptors in the skin. The prescribing information notes that this pigmentation may not be reversible after stopping the drug. Women with naturally darker skin tones or a personal history of melasma, which is more common in women with prior oral contraceptive use or prior pregnancies, may face higher risk. Melasma itself becomes less common after menopause due to lower estrogen, but residual post-inflammatory hyperpigmentation from prior melasma can still be present in women in their 50s.

Drug Interactions at This Life Stage

Women in their 50s are statistically more likely to take multiple medications: antihypertensives, antidepressants, statins, thyroid medications, or menopausal hormone therapy (MHT). Bremelanotide slows gastric emptying, which can reduce the absorption of oral medications taken around the same time. The FDA label specifically warns against using bremelanotide with naltrexone, because it antagonizes bremelanotide's mechanism. Women using low-dose naltrexone off-label for immune conditions or mood should discuss this conflict with their prescriber.

Pregnancy, Lactation, and Contraception: What Women in Their 50s Need to Know

This section matters less for fully postmenopausal women, but it remains relevant for women in their 50s who are still in perimenopause and may still be capable of conception.

Pregnancy Safety

Bremelanotide is contraindicated in pregnancy. Animal reproductive studies showed embryofetal toxicity at doses relevant to human exposure, including fetal loss and reduced fetal weight. There are no adequate and well-controlled human pregnancy studies. The FDA label assigns no formal pregnancy category under the older A/B/C/D/X system because it was approved under the newer 2015 labeling rules, but the label language is unambiguous: do not use during pregnancy.

Contraception Requirement for Perimenopausal Women

If you are in perimenopause and still having any menstrual cycles, you can still ovulate and conceive, even if your cycles are irregular. ACOG recommends that perimenopausal women use contraception until 12 months after the final menstrual period because ovulation remains possible even with long gaps between periods. If you are using Vyleesi and are perimenopausal, you need reliable contraception. Combined hormonal contraceptives interact with the blood pressure effects and are not ideal for many women in their 50s. Progestin-only options or non-hormonal IUDs are generally preferable choices.

Lactation

Bremelanotide has not been studied in lactating women, and it is not known whether it transfers into human milk. Given that women in their 50s are rarely lactating, this is primarily relevant for context. If you are a woman in your 50s who is postpartum after a late-in-life pregnancy and breastfeeding, do not use bremelanotide.

What Conditions at This Life Stage Make HSDD More Complex?

At 50-plus, desire disorders rarely exist in isolation. Several conditions common in this age group compound low desire in ways that bremelanotide alone cannot address.

Genitourinary Syndrome of Menopause (GSM)

GSM affects an estimated 27 to 84% of postmenopausal women and includes vaginal dryness, thinning of vaginal tissue, and pain with sex (dyspareunia). If pain is a primary driver of desire avoidance, a central nervous system drug like bremelanotide is unlikely to overcome the learned association between sex and discomfort. Treating GSM first, with local vaginal estrogen, ospemifene, or DHEA (prasterone), is typically the more logical starting point.

Thyroid Dysfunction

Hypothyroidism is significantly more prevalent in women, particularly after 50, and it is a known cause of reduced libido. The American Thyroid Association estimates that women are five to eight times more likely than men to develop thyroid disease. If thyroid-stimulating hormone (TSH) has not been checked recently and desire has changed, ruling out hypothyroidism before adding a sexual-function drug is standard clinical practice.

Depression and Antidepressant Use

Many women in their 50s use SSRIs or SNRIs for depression, anxiety, or hot flash management. SSRI-induced sexual dysfunction, including reduced desire, arousal, and orgasm, is one of the most common medication side effects in this age group. Bremelanotide was not formally studied on top of antidepressants in the RECONNECT trials, and the interaction has not been characterized well. Switching to bupropion or mirtazapine, or adding a very low dose of bupropion, has more direct evidence for antidepressant-related desire loss than bremelanotide does.

Who Vyleesi Is and Is Not Right for at This Life Stage

Not every woman in her 50s with low desire is a candidate for bremelanotide. Here is a structured way to think about fit:

Women for Whom Vyleesi May Be a Reasonable Option

• Perimenopausal women who still have menstrual cycles, have received a formal HSDD diagnosis, have been screened for and do not have cardiovascular disease or uncontrolled hypertension, and have not responded to psychosexual therapy or other interventions.
• Women with HSDD who are not candidates for hormonal therapy and whose desire loss is not primarily driven by pain or GSM.
• Women who have discussed off-label use explicitly with a knowledgeable clinician and understand the limitations of extrapolating RECONNECT data to their life stage.

Women for Whom Vyleesi Is Not Appropriate

• Fully postmenopausal women seeking an FDA-approved treatment (off-label use must be discussed explicitly).
• Women with hypertension, a history of cardiovascular disease, or a prior stroke or transient ischemic attack.
• Women with significant GSM or pain with sex as the primary driver of desire avoidance.
• Women whose desire loss is clearly secondary to depression, untreated hypothyroidism, relationship distress, or antidepressant side effects.
• Women with a history of focal hyperpigmentation disorders or who have strong cosmetic concerns about skin pigmentation.

How Vyleesi Compares to Other HSDD Options in Your 50s

Two FDA-approved treatments exist for HSDD, and bremelanotide is one of them. The other is flibanserin (Addyi), an oral daily medication that acts on serotonin and dopamine receptors. Flibanserin is also approved only for premenopausal women and carries a black box warning about hypotension with alcohol, making it particularly challenging for social drinkers.

For postmenopausal women, no drug carries an FDA approval specifically for HSDD. The Menopause Society (formerly NAMS) 2022 position statement on sexual health notes that testosterone therapy, while not FDA-approved for women, has the strongest evidence base for desire improvement in postmenopausal women, with multiple randomized controlled trials supporting a modest but real benefit when used at physiologic doses.

A head-to-head framework for women in their 50s might look like this:

| Option | FDA Approval in Postmenopausal Women | Evidence Level | Key Risk | |---|---|---|---| | Bremelanotide (Vyleesi) | No (premenopausal only) | Phase 3 in premenopausal; extrapolated | Hypertension, nausea, pigmentation | | Flibanserin (Addyi) | No (premenopausal only) | Phase 3 in premenopausal; extrapolated | Hypotension, sedation, alcohol interaction | | Testosterone (off-label) | No (no female indication exists) | Multiple RCTs in postmenopausal women | Acne, hair changes, limited long-term safety data | | Local vaginal estrogen | Yes (for GSM, not HSDD) | Extensive RCT data | Minimal systemic absorption | | Prasterone (Intrarosa) | Yes (for dyspareunia in menopause) | Phase 3 in postmenopausal women | Localized; minimal systemic DHEA conversion |

The evidence gap for Vyleesi in postmenopausal women is real and worth naming plainly: the drug may help, but you would be using it based on mechanism and extrapolation, not on a trial designed to answer your specific clinical question.

Practical Dosing and Administration for Women in Their 50s

The standard dose is 1.75 mg subcutaneous injection administered to the abdomen or thigh approximately 45 minutes before anticipated sexual activity. The auto-injector is pre-filled. You do not need refrigeration after dispensing.

No dose adjustment is recommended for age alone in the prescribing information, but that guidance is based on a trial population that did not formally include women over 55. The blood pressure monitoring recommendation applies regardless of age: your prescriber should measure your blood pressure before the first dose and have a plan if it rises.

A few practical points for women at this life stage:

• Nausea is worse on an empty stomach. Eating a light meal before injecting reduces severity in most users.
• The 24-hour limit between doses is firm. No more than eight doses per month were used in clinical trials.
• If you are using oral medications for blood pressure or thyroid, inject bremelanotide at least two hours after taking those medications, given the gastric motility effect.
• Skin rotation is important. Repeated injections at the same site increase local pigmentation risk.

The Evidence Gap: What We Do Not Know Yet

Women in their 50s have been underserved by sexual health research. The RECONNECT trials enrolled just over 1,200 women across both studies, and the postmenopausal experience was not analyzed as a subgroup. A 2016 systematic review in the Journal of Sexual Medicine highlighted that most HSDD trial populations skew toward younger premenopausal participants, leaving perimenopausal and postmenopausal women with limited directly applicable data.

This is not unique to bremelanotide. It reflects a broader history of women being enrolled in trials primarily during their reproductive years, with menopause often treated as an exclusion criterion rather than a distinct clinical population worth studying. At WomanRx, our clinical reviewers apply an explicit framework when evaluating evidence in this age group: we distinguish between data that is directly applicable, data that is plausibly extrapolated based on mechanism, and data that simply does not exist yet.

For bremelanotide in postmenopausal women: the mechanism is plausible, the extrapolation is reasonable as a hypothesis, but direct phase 3 evidence in this population does not currently exist. Any prescriber presenting this drug to you as "proven to work in menopause" is overstating the evidence.

A useful three-tier way to frame your conversation with your clinician:

Tier 1: Address the reversible causes first. Treat GSM, screen for thyroid dysfunction, assess depression and medication side effects. These are modifiable and have strong evidence.

Tier 2: Consider testosterone therapy. For postmenopausal HSDD, testosterone has a stronger evidence base than bremelanotide, even without an FDA approval for women. The Menopause Society supports a clinical trial of testosterone in appropriately selected postmenopausal women with HSDD.

Tier 3: Consider bremelanotide off-label if Tier 1 and Tier 2 have been addressed and HSDD persists, you have a documented HSDD diagnosis, your cardiovascular risk is low, and you have had a frank conversation about the limitations of the evidence.